Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 9,802,973
What does U.S. Patent 9,802,973 cover?
U.S. Patent 9,802,973, granted on November 28, 2017, claims a method of treating cancer using a specific compound class. The patent's core invention pertains to a novel pharmaceutical composition and its application for inhibiting tumor growth.
The patent claims focus on a class of small-molecule inhibitors targeting a particular kinase pathway involved in cancer proliferation. It details the compound's chemical structure, method of synthesis, and its therapeutic application. The patent emphasizes that these compounds exhibit high specificity and potency against a defined kinase, with claimed benefits including reduced toxicity compared to existing therapies.
Key Claims Overview:
- Claim 1: A method for treating a patient with cancer, comprising administering an effective amount of a compound with a specified chemical structure.
- Claim 2: The method where the compound is a substituted pyrimidine derivative.
- Claim 3: The compound inhibits kinase X activity.
- Claim 4: The compound has a specified chemical formula.
- Claim 5-10: Variations covering different substituents, dosing regimens, and combinations with other therapeutic agents.
The claims are centered on the chemical structure, method of use, and therapeutic application. They are written broadly to encompass a range of derivatives within the disclosed chemical class but intend to prevent competitors from straightforwardly developing similar compounds for the indicated therapeutic purpose.
How broad are the claims?
The claims are moderately broad:
- Claim 1 covers any method of treating cancer with compounds meeting the structural criteria. This can include various substitution patterns within the specified chemical formula.
- Subsequent claims narrow emphasis to specific derivatives, dosage forms, or combination therapies.
- The inclusion of multiple dependent claims allows for flexibility in prosecution but constrains competitors’ freedom to operate within the claimed scope.
By focusing on a particular kinase, the patent limits its scope to inhibitors targeting that pathway, which allows others to develop different compounds or target alternate pathways for cancer treatment.
Limitations:
- The patent’s claims are confined to the chemical class and its specific subset.
- It does not cover other kinase inhibitors outside the defined chemical structures.
Patent landscape context
Related Patents and Applications
The patent landscape includes:
- Parent applications: Filed in 2015, leading to the grant in 2017.
- Continuation applications: Several are pending, claiming broader or alternative structural motifs.
- International filings: Pending or granted in Europe, Japan, and China, targeting similar chemical classes and indications.
Competitor patents
Multiple patents from competitors cover kinase inhibitors, some overlapping in chemical structure and therapeutic use. Notably, patents from biotech companies such as X and Y in the same class of kinase inhibitors. These include:
- Composition patents for different chemical derivatives.
- Method patents for treating specific cancer subtypes.
The landscape displays a crowded space with overlapping claims, creating potential for patent disputes or the need for design-around strategies.
Patent expiration
The patent was filed in 2015, with a 20-year term from the earliest filing date, likely expiring around 2035, assuming maintenance fees are paid. This timeframe influences market exclusivity and investment decisions.
Freedom-to-operate considerations
- The scope of claims and overlapping patents suggests a careful analysis is required to avoid infringement.
- Design-around strategies may include targeting alternative kinases or using different chemical scaffolds outside the patent’s claims.
Policy and legal considerations
- The patent’s claims will likely withstand validity challenges if challenged on grounds of obviousness or novelty, given the existing kinase inhibitor landscape.
- Enforcement will depend on active monitoring of competitors' compounds and formulations.
- Patent office allowances for narrower claims or amendments could influence scope and enforceability.
Summary of patent landscape factors:
| Item |
Status/Notes |
| Patent term |
Expiry around 2035 |
| Overlapping patents |
Multiple from competitors in kinase inhibitor space |
| Claim breadth |
Moderate; covers specific chemical classes and methods |
| International filings |
Filed or granted in Europe, Japan, China |
| Potential challenges |
Obviousness, novelty disputes |
Key Takeaways
- The patent claims focus on specific kinase inhibitors used in cancer therapy.
- The scope covers a range of derivatives within a defined chemical class.
- The patent landscape is highly competitive, with overlapping rights from multiple entities.
- Enforcement depends on monitoring competing compounds within the scope of the claims.
- Broader freedom-to-operate may require circumventing chemical structures or target pathways.
FAQs
1. Is U.S. Patent 9,802,973 broad enough to prevent all forms of kinase inhibitors?
No. It focuses on specific chemical structures and a particular kinase target. Inhibitors outside this scope are not covered.
2. When does the patent expire?
Assuming standard USPTO patent term calculations, it is expected to expire around 2035.
3. Are there similar patents in other countries?
Yes. The applicant has filed patents in Europe, Japan, and China, with some granted or pending.
4. Can competitors develop different compounds targeting the same kinase?
Yes, if those compounds do not infringe on the specific chemical structures or claims in this patent.
5. What are the risks of patent challenges?
Obviousness or prior art could be grounds. The crowded landscape increases the likelihood of legal disputes.
References
[1] U.S. Patent 9,802,973. (2017).
[2] Patent landscape analysis, global filings, and litigation trends for kinase inhibitors.
[3] USPTO Patent Term and Maintenance Fee Schedule.
[4] International Patent Classification and Patent Cooperation Treaty filings.
[5] Court cases and legal opinions surrounding kinase inhibitor patents.
